Hls Therapeutics Stock Analysis
| HLS Stock | CAD 4.90 0.01 0.20% |
HLS Therapeutics is overvalued with Real Value of 3.99 and Hype Value of 4.89. The main objective of HLS Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what HLS Therapeutics is worth, separate from its market price. There are two main types of HLS Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect HLS Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of HLS Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The HLS Therapeutics stock is traded in Canada on Toronto Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. HLS Therapeutics is usually not traded on Family Day, Good Friday, Victoria Day, Canada Day, Civic Holiday, Labour Day, Christmas Day, Boxing Day, New Year 's Day. HLS Stock trading window is adjusted to America/Toronto timezone.
HLS |
HLS Stock Analysis Notes
About 45.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. HLS Therapeutics recorded a loss per share of 0.78. The entity last dividend was issued on the 27th of April 2023. The firm had 1:5 split on the 26th of October 2006. HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. HLS THERAPEUTICS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 46 people. To learn more about HLS Therapeutics call Gilbert Godin at 647 495 9000 or check out https://www.hlstherapeutics.com.HLS Therapeutics Investment Alerts
| The company reported the revenue of 56.62 M. Net Loss for the year was (19.66 M) with profit before overhead, payroll, taxes, and interest of 41.31 M. |
HLS Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 155.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate HLS Therapeutics's market, we take the total number of its shares issued and multiply it by HLS Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.HLS Profitablity
HLS Therapeutics' profitability indicators refer to fundamental financial ratios that showcase HLS Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, HLS Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, HLS Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of HLS Therapeutics' profitability requires more research than a typical breakdown of HLS Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.32) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.17) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.17. Technical Drivers
As of the 21st of July, HLS Therapeutics retains the market risk adjusted performance of (2.56), and Risk Adjusted Performance of 0.1315. HLS Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.HLS Therapeutics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Simple Moving Average indicator is calculated by adding the closing price of HLS Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out HLS Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
HLS Therapeutics Outstanding Bonds
HLS Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. HLS Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most HLS bonds can be classified according to their maturity, which is the date when HLS Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
HLS Therapeutics Predictive Daily Indicators
HLS Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of HLS Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
HLS Therapeutics Forecast Models
HLS Therapeutics' time-series forecasting models are one of many HLS Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary HLS Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About HLS Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how HLS Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling HLS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as HLS Therapeutics. By using and applying HLS Stock analysis, traders can create a robust methodology for identifying HLS entry and exit points for their positions.
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. HLS THERAPEUTICS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 46 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding HLS Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.